Overview
- Pivotal Ventures and Wellcome Leap are committing $50 million each to a new $100 million fund to accelerate women’s health research.
- The effort will concentrate on conditions that affect women differently or disproportionately, including cardiovascular disease, autoimmune disorders and mental health.
- Two priority programs will be selected by the end of 2026, with launches planned for 2026 and targeted outcomes in three to five years.
- Organizers cite a persistent funding gap, noting that only about 1% of pharmaceutical research outside cancer went to women’s health in 2024.
- With this partnership, Wellcome Leap’s women’s health commitments rise toward $250 million as it pursues $1 billion in philanthropic capital, complementing the Gates Foundation’s recent $2.5 billion pledge through 2030.